Physician profile
Elva Lopez
NPI 1871503706
$1,657.28
in general payments reported to CMS, 2019-2025
23 companies · $249 in 2025
The $249 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $73.17 · 2020: $138 · 2021: $574 · 2022: $179 · 2023: $217 · 2024: $227 · 2025: $249.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $692.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $692.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acessa Health INC. | $359.38 | 2021 | |
| Hologic Sales and Service, LLC | $338.76 | 2019-2025 | Myosure Tissue Removal Device, Acessa Provu System |
| Nevro Corp. | $166.00 | 2022-2023 | Senza |
| Novo Nordisk INC | $108.46 | 2019-2021 | |
| Smith+Nephew, INC. | $98.80 | 2025 | Stravix Pl |
| Organon LLC | $75.65 | 2021-2025 | Nexplanon |
| Abbvie INC. | $62.14 | 2021-2023 | |
| Ethicon US, LLC | $61.81 | 2021-2024 | Ethicon, Enseal |
| Pfizer INC. | $44.31 | 2024-2025 | |
| Applied Medical Resources Corporation | $43.99 | 2023 | |
| Vertex Pharmaceuticals Incorporated | $33.17 | 2025 | |
| Qol Medical, LLC | $33.14 | 2024 | Sucraid |
| Sage Therapeutics, LLC | $28.90 | 2024 | |
| Merck Sharp & Dohme LLC | $27.60 | 2020-2021 | |
| Viiv Healthcare Company | $27.41 | 2023 | Rukobia |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.21 | 2024 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $23.11 | 2023 | |
| Sunovion Pharmaceuticals INC. | $22.23 | 2019 | |
| Lilly USA, LLC | $19.74 | 2024 | Zepbound |
| Teleflex LLC | $16.33 | 2021 | |
| Organogenesis INC. | $15.67 | 2019 | |
| Astellas Pharma US INC | $13.82 | 2024 | Veozah |
| Daiichi Sankyo INC. | $13.65 | 2024 | Injectafer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elva Lopez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.